Company Active LTD

Company profile

Revive Innovations + Limited

Revive Innovation

Want to help? We're looking for users to help us offer the best usability features in an auto-injector! Sounds great. I want to sign up! About Us Revive Innovations is current developing a pre-loaded injection device that administers life-saving adrenaline, while utilizing a compact and patient centric form-factor. Our objective is to leverage user-centric design

CRN
12138353
Founded
2019
Age
6

Overview

Legal name
REVIVE INNOVATIONS + LIMITED
Region
London
Registered address
124 CITY ROAD
LONDON
ENGLAND
EC1V 2NX
Insolvency history
No

Latest accounts

Financial period: 1 Apr 2024 to 31 Mar 2025

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
3

Company events

Reference milestones and recent Companies House filing stream events.

6 events
31 Dec
2027

Accounts due

Accounts Due

Next accounts due date

14 Mar
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Mar
2026

Accounts filed

Accounts

Last accounts made up date

28 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

26 Nov
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0NDk0NDA4NmFkaXF6a2N4

Published 26 Nov 2024 03:13

05 Aug
2019

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2020
Funded years
2020, 2022
Age at first award
1 years

Projects

2022 Collaborative R&D Lead participant

Revive Adrenaline Auto-injector: Industrial Research

1 Jun 2022 to 30 Jun 2023

Awarded
£583,978
Total cost £834,255

An adrenaline auto-injector (AAI) is prescribed to people who are susceptible to severe allergies that put them at risk of anaphylaxis -- a life threatening allergic reaction. Despite medical advice to carry the injector on person at all times, our user studies show: 1. People do not carry them nearly as much as they should 2. Not receiving adrenaline for...

2020 Study Lead participant

Technical feasibility for the Revive + Adrenaline Auto-injector

1 Nov 2020 to 31 Jan 2022

Awarded
£190,670
Total cost £272,386

An adrenaline auto-injector (AAI) is prescribed to people who are susceptible to severe allergies that put them at risk of anaphylaxis -- a life threatening allergic reaction. Despite medical advice to carry the injector on person at all times, our user studies show: 1. People do not carry them nearly as much as they should 2. Not receiving adrenaline for...

Product types

Collaborative R&D Study